| Abstrakt: |
Osteoarthritis (OA) is the most common joint disease and the main cause of joint dysfunction and disability. Despite advances in the study of the pathogenesis of this disease, its treatment remains a challenge. Currently, nonsteroidal anti-inflammatory drugs (NSAIDs), analgesics, and glucocorticosteroids are used as options for the pharmacological treatment of OA to control pain and inflammation. However, they act as symptomatic treatment and have a high risk of side effects. Symptomatic slow-acting drugs (SYSADOA) for the treatment of OA are not fast-acting, such as NSAIDs, and their clinical effectiveness in reducing OA symptoms can be demonstrated only after a few weeks of regular administration. However, with OA, they not only reduce pain in the joints but also slow down the progression of the disease. One of these drugs is chondroitin sulfate, a complex heterogeneous polysaccharide that has an excellent safety profile. It is chondroitin sulfate and glucosamine sulfate that have recently gained widespread use as variants of SYSADOA for the treatment of OA. They act as chondroprotectors and/or as “disease-modifying drugs in OA” that relieve pain and partially restore joint function in OA patients, and thus exhibit not only symptomatic treatment but also influence on the pathogenetic links of OA. Chondroitin sulfate reduces the activity of pro-inflammatory cytokines and transcription factors involved in inflammation. Glucosamine sulfate strengthens specific components of the cartilage matrix and prevents collagen degeneration in chondrocytes by inhibiting hydrolytic enzymes. Clinical studies of chondroitin sulfate in the treatment of OA have shown that it is effective, safe, and well-tolerated. Therefore, the use of SYSADOA drugs reduces the use of NSAIDs in the treatment of OA and reduces the risk of their side effects. Objective: to collect and analyze the literature on the therapeutic efficacy of symptomatic slow-acting drugs (SYSADOA) in the treatment of OA. Methods. The search for scientific information was carried out in PubMed electronic databases, Google Scholar. Results. A review and analysis of the literature on the therapeutic efficacy of SYSADOA in the treatment of OA was performed. Conclusions. Symptomatic slow-acting drugs reduce pain, stiffness, functional limitations in OA and have a good safety profile. [ABSTRACT FROM AUTHOR] |
